Lexeo Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $LXEO in the last 30 days.
See all $LXEO insider activity →U.S. stock futures were mixed on Tuesday. Ericsson (NASDAQ:ERIC) fell 4.3% to $9.81 after a Morgan Stanley analyst downgraded it and cut the price target. Other stocks moving lower include Quest Diagnostics (NYSE:DGX), Rambus (NASDAQ:RMBS), and Lexeo Therapeutics (NASDAQ:LXEO).
Lexeo Therapeutics, Inc. (LXEO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace f
Lexeo Therapeutics, Inc. (LXEO) reported beneficial ownership disclosures by OrbiMed entities. OrbiMed Advisors LLC holds 3,203,050 shares, about 4.1% of the class, and OrbiMed Capital LLC holds 744,800 shares, about 1.0%. Combined, they report 5.0% ownership with shared voting and dispositive control via a management committee.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning LXEO (Lexeo Therapeutics, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent LXEO coverage spans technology, financial news and market movers.
Acquisition announcement and collaborations create short‑term volatility.
The acquisition expands Lexeo's Friedreich ataxia pipeline and may boost its valuation as the market prices in new assets and cash‑rich balance sheet.
This is a new ownership disclosure that can affect perceived control, liquidity, and potential future activism or financing narratives, but it is not an operational catalyst.
This is a beneficial-ownership disclosure that can matter for control perception and potential activism risk, but it does not announce a new operational catalyst.
Trial initiation and RMAT designation updates improve near-term clinical/regulatory visibility, but the next major inflection is 2H27 topline.
AlphAI scores every news story that mentions LXEO with an AI model for sentiment and relevance, and aggregates insider trades from Lexeo Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
U.S. stock futures were mixed on Tuesday. Ericsson (NASDAQ:ERIC) fell 4.3% to $9.81 after a Morgan Stanley analyst downgraded it and cut the price target. Other stocks moving lower include Quest Diagnostics (NYSE:DGX), Rambus (NASDAQ:RMBS), and Lexeo Therapeutics (NASDAQ:LXEO).
1 min readLexeo Therapeutics, Inc. (LXEO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace f
2 min readLexeo Therapeutics, Inc. (LXEO) reported beneficial ownership disclosures by OrbiMed entities. OrbiMed Advisors LLC holds 3,203,050 shares, about 4.1% of the class, and OrbiMed Capital LLC holds 744,800 shares, about 1.0%. Combined, they report 5.0% ownership with shared voting and dispositive control via a management committee.
2 min readLexeo Therapeutics (LXEO) disclosed in a Schedule 13G/A (Amendment No. 3) that Paradigm BioCapital-related entities and Senai Asefaw, M.D. hold beneficial ownership of its common stock. Paradigm BioCapital Advisors LP, GP LLC and Asefaw report 4,175,382 shares, 5.3% of the class, and Paradigm BioCapital International Fund Ltd. reports 3,662,102 shares, 4.7%, based on 78,521,634 shares outstanding as of May 7, 2026.
2 min readLexeo Therapeutics (LXEO) reported Q2 2026 results and updates. It initiated the SUNRISE-FA 2 pivotal trial for LX2006 in June 2026, with first site activated and first patient enrolled. FDA granted RMAT designation for LX2020. Q2 R&D was $19.0M, net loss $25.9M ($0.30/share). Cash was $234.2M. Topline LX2006 data expected 2H 2027.
5 min readLexeo Therapeutics (Nasdaq: LXEO) reported Q2 2026 results and updates. It finalized SUNRISE-FA 2 protocol and SAP for LX2006, with first patient enrolled in June and site activation ongoing. CLARITY-FA enrollment continues. FDA granted RMAT for LX2020. Cash and investments were $234.2M, funding operations into 2028. R&D was $19.0M and net loss $25.9M ($0.30/share).
4 min readLexeo Therapeutics, Inc. (LXEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated
5 min readLexeo Therapeutics (Nasdaq: LXEO) said the FDA granted RMAT designation to its investigational AAV-based gene therapy LX2020 for PKP2-associated arrhythmogenic cardiomyopathy. The decision was based on interim data from the ongoing HEROIC-PKP2 Phase I/II trial. Lexeo also noted LX2020 received Orphan Drug and Fast Track designations.
3 min readLexeo Therapeutics (NASDAQ:LXEO) said it finalized the critical trial protocol and statistical analysis plan for SUNRISE-FA 2, supporting a Biologics License Application to the U.S. FDA for gene therapy candidate LX2006 under the 2028 approval pathway. JPMorgan cut its target to $9 from $12 and kept an Overweight rating.
4 min readTownsend Richard Nolan (Chief Executive Officer) sold 25,947 shares of Lexeo Therapeutics, Inc. (LXEO) at $4.48 ($0.12M total) on 2026-07-01.
2 min read